Failure to Launch: Biosimilar Sales Continue to Fall Flat in the United States
- PMID: 31922346
- PMCID: PMC7255927
- DOI: 10.1002/art.41203
Failure to Launch: Biosimilar Sales Continue to Fall Flat in the United States
Comment on
-
Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States.Arthritis Rheumatol. 2020 Jun;72(6):1036-1038. doi: 10.1002/art.41201. Epub 2020 Apr 7. Arthritis Rheumatol. 2020. PMID: 31943866 No abstract available.
References
-
- Brill A, Ippolito B. The Economics of Biologic Drugs: A Further Response to Bach et al., Health Affairs Blog, August 8, 2019.
-
- Jensen TB, Bartels D, Sædder EA et al. Eur J Clin Pharmacol (2019).
-
- Use of Step Through Policies for Competitive Biologics Among Commercial U.S. Insurers. Avalere Health. May 2018. https://avalere.com/insights/use-of-step-through-policies-for-competitiv.... Accessed December 8, 2019.
-
- Price WN, Rai AK How logically impossible patents block biosimilars. Nat Biotechnol 37, 862–863 (2019). - PubMed
-
- Overpatented and Overpriced. http://www.i-mak.org/wp-content/uploads/2018/09/i-mak.humira.report.fina.... Accessed December 8, 2019.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
